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A bs tr ac t
Background
Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required 
to consolidate remission and prevent relapse after the initial control of lupus nephritis.
Methods
We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 study 
comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per 
kilogram of body weight per day), plus placebo in each group, in patients who met re-
sponse criteria during a 6-month induction trial. The study group underwent repeat 
randomization in a 1:1 ratio. Up to 10 mg of prednisone per day or its equivalent was 
permitted. The primary efficacy end point was the time to treatment failure, which was 
defined as death, end-stage renal disease, doubling of the serum creatinine level, renal 
flare, or rescue therapy for lupus nephritis. Secondary assessments included the time 
to the individual components of treatment failure and adverse events.
Results
A total of 227 patients were randomly assigned to maintenance treatment (116 to 
mycophenolate mofetil and 111 to azathioprine). Mycophenolate mofetil was superior 
to azathioprine with respect to the primary end point, time to treatment failure (hazard 
ratio, 0.44; 95% confidence interval, 0.25 to 0.77; P = 0.003), and with respect to time 
to renal flare and time to rescue therapy (hazard ratio, <1.00; P<0.05). Observed rates 
of treatment failure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group 
and 32.4% (36 of 111) in the azathioprine group. Adverse events, most commonly minor 
infections and gastrointestinal disorders, occurred in more than 95% of the patients 
in both groups (P = 0.68). Serious adverse events occurred in 33.3% of patients in the 
azathioprine group and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), 
and the rate of withdrawal due to adverse events was higher with azathioprine than with 
mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).
Conclusions
Mycophenolate mofetil was superior to azathioprine in maintaining a renal response 
to treatment and in preventing relapse in patients with lupus nephritis who had a 
response to induction therapy. (Funded by Vifor Pharma [formerly Aspreva]; ALMS 
ClinicalTrials.gov number, NCT00377637.)
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Systemic lupus erythematosus is an autoimmune disorder often characterized by the development of glomerulonephritis.1 Re-
nal involvement remains the strongest predictor of 
morbidity and mortality among patients with lu-
pus,1 and despite improvements in the manage-
ment of lupus, the incidence of end-stage renal 
disease has not declined.2 Management of lupus 
nephritis consists of induction therapy to achieve 
remission and long-term maintenance therapy to 
prevent relapse, progression to end-stage renal dis-
ease, and death.3 However, the options for long-
term therapy remain controversial. Treatment 
options include glucocorticoids and the immuno-
suppressive agents cyclophosphamide, azathio-
prine, and mycophenolate mofetil. These drugs 
have considerable toxicity and are not effective in 
all patients.4,5
There has been mounting interest in the use of 
mycophenolate mofetil as induction therapy, main-
tenance therapy, or both for patients with lupus 
nephritis.6-12 The Aspreva Lupus Management 
Study (ALMS), which examined the efficacy and 
safety of induction therapy with mycophenolate 
mofetil as compared with intravenous cyclophos-
phamide (plus standardized tapering of gluco-
corticoid therapy) in patients with active lupus 
nephritis (renal-biopsy active class III, IV, or V13-16 
[according to the International Society of Ne-
phrology and Renal Pathology Society 2003 Clas-
sification of Lupus Nephritis17]), showed no sig-
nificant difference between the two drugs.13 (For 
a description of the classes of renal biopsy used in 
this study, see the protocol, available with the full 
text of this article at NEJM.org.) Here we report the 
results of a 36-month study of maintenance thera-
py with either mycophenolate mofetil or azathio-
prine in patients who had a specified response to 
treatment during the ALMS induction study.
Me thods
Study Design and Oversight
We conducted a prospective, randomized, double-
blind, double-dummy, phase 3 study comparing 
mycophenolate mofetil (CellCept, Roche) with aza-
thioprine (Imuran, GlaxoSmithKline) for the main-
tenance of remission in patients with lupus nephri-
tis. Results of the induction study and detailed 
descriptions of methods for both phases have been 
reported previously.13,18 The study was conducted 
in accordance with the Declaration of Helsinki and 
Good Clinical Practice principles. The institution-
al review boards at the participating centers ap-
proved the protocol, and all patients or their repre-
sentatives provided written informed consent. The 
study was conducted in accordance with the proto-
col and all amendments.
The study was funded by Vifor Pharma (for-
merly Aspreva Pharmaceuticals) as part of the 
Roche–Aspreva rare diseases collaboration. All the 
investigators have confidentiality agreements with 
Vifor Pharma. Seven of the academic authors and 
two authors who are employees of the sponsor 
conceived of and designed the study, seven of the 
academic authors collected the data, and all the 
authors analyzed and interpreted the data. The 
manuscript was drafted initially by medical writers 
from Caudex Medical (Oxford, United Kingdom), 
with funding from Vifor Pharma and in line with 
guidance from all the authors. It was then amend-
ed substantially, critically reviewed, and edited by 
all the authors, who approved the final version, 
made the decision to submit the manuscript for 
publication, and vouch for the completeness and 
accuracy of the reported data.
Study Participants
Patients 12 to 75 years of age with active class III, 
IV, or V lupus nephritis who had had a clinical re-
sponse to either oral mycophenolate mofetil or in-
travenous cyclophosphamide during the induction 
study13 were randomly assigned (in a 1:1 ratio) to 
one of these two agents in the maintenance study. 
The definition of a response was based on investi-
gator judgment but was not necessarily identical to 
that finally adjudicated by the clinical end-points 
committee. The maintenance study treatment was 
randomly assigned by means of a computerized, 
interactive voice-response system, with stratifica-
tion according to induction study treatment, race, 
and classification of renal biopsy.
Patients were followed for 36 months, regard-
less of events. The vital status of patients who 
withdrew (with the exception of those who with-
drew consent) was obtained annually for 3 years. 
Patients who completed the 36-month study were 
contacted 30 days after the last visit to obtain in-
formation about any adverse events and use of 
concomitant medications.
Interventions and Schedule of Assessments
At the end of the 24-week induction study, patients 
received oral mycophenolate mofetil (1 g, twice 
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daily) or oral azathioprine (2 mg per kilogram of 
body weight per day). Patients who were unable to 
tolerate the target dose or whose weight was below 
50 kg remained in the study if they tolerated a min-
imum dose of either 1 g of mycophenolate mofetil 
per day or 50 mg of azathioprine per day. Tempo-
rary reductions below the minimum dose or com-
plete cessation of the drug for no more than 14 days 
was allowed. Any dose changes were made to both 
active drug and placebo. Patients could receive 
prednisone or its equivalent (maximum dose, 10 mg 
per day), with the dose reduced on the basis of the 
investigator’s judgment.
Patients were assessed at months 0, 1, and 2 and 
every 3 months thereafter until month 36; at early 
withdrawal; or at termination due to treatment 
failure. Selected safety and efficacy evaluations 
were made at every visit, and patients were con-
tacted by telephone monthly to obtain information 
about use of concomitant medications. Changes in 
the doses of angiotensin-converting–enzyme in-
hibitors, angiotensin-receptor blockers, and non-
steroidal antiinflammatory agents had to be ap-
proved by the medical study monitor.
The protocol was amended in April 2009, after 
discussion with representatives of the European 
and U.S. health authorities, to make the primary 
end point more specific for events related to lupus 
nephritis and to provide a broader definition of 
treatment failure (the original primary end point 
was included as a key secondary end point). (The 
protocol and all amendments can be found at 
NEJM.org.)
Outcomes
The primary efficacy end point was the time to 
treatment failure, measured as the time until the 
first event and defined as death, end-stage renal 
disease, sustained doubling of the serum creatinine 
level, renal flare (proteinuric or nephritic), or the 
need for rescue therapy (glucocorticoids, plasma-
pheresis, intravenous immune globulin, or immu-
nosuppressive drugs not specified in the protocol) 
in the event of exacerbation or deterioration of lu-
pus nephritis. A more detailed description of the 
study outcomes has been reported previously18 and 
is provided in the Supplementary Appendix, avail-
able at NEJM.org. Proteinuric renal flare was de-
fined as a doubling of the urinary protein:creatinine 
ratio and proteinuria (≥1 g of protein per 24 hours 
in patients with urinary protein clearance of ≤0.5 g 
per 24 hours at the end of induction, and ≥2 g per 
24 hours in patients with urinary protein clearance 
of >0.5 g per 24 hours at the end of induction). 
Nephritic renal flare was defined as an increase of 
25% or more in the lowest serum creatinine level 
during the period from screening to the end of 
induction, plus one or more of the following find-
ings: simultaneous doubling of urinary protein 
clearance, reaching a minimum of 2 g per 24 hours 
(or the urinary protein:creatinine ratio equivalent); 
new or increased hematuria (≥5 red cells per high-
power field or ≥2+ on a dipstick test for blood); or 
the appearance of cellular casts.
Key secondary end points included the time to 
the event for each component of treatment failure, 
the time to treatment failure defined more broad-
ly (i.e., the components of the primary end point, 
major extrarenal flare, or withdrawal for any 
reason), suspected renal flare, complete renal re-
mission (urinary protein clearance, <500 mg per 
24 hours; absence of hematuria and cellular casts; 
and improved or stable serum creatinine ±25% of 
baseline), combined renal and extrarenal remission 
(absence of a British Isles Lupus Assessment Group 
category A score [severe lupus flare] in one extra-
renal system or lack of a concurrent category B 
score [moderate lupus flare] in three extrarenal 
systems19), and immunologic variables (C3, C4, 
and anti–double-stranded DNA antibodies).
Safety assessments included clinical measure-
ments (hematologic, serum chemical, and hor-
monal tests and urinalysis), adverse events, physi-
cal examination, vital signs, electrocardiographic 
studies, and assessment of prior and concomitant 
medications. As specified by the protocol, to avoid 
bias, the independent clinical end-points com-
mittee, whose members were unaware of the 
treatment assignments and adverse-event listings, 
reviewed all results and adjudicated each compo-
nent of the primary end point and several second-
ary end points (i.e., suspected renal flare, major or 
suspected extrarenal flare, and complete extrare-
nal remission).
Statistical Analysis
We calculated that we would need to assign 
114 patients to each group for the maintenance 
study to have 80% or higher power to detect differ-
ences between treatments, assuming a failure rate 
at 3 years of 37.5% with azathioprine and 20.0% 
with mycophenolate mofetil (hazard ratio with my-
cophenolate mofetil, 0.475), with the use of a log-
rank test at a two-sided significance level of 0.05.
The primary efficacy analysis was an intention-
to-treat analysis that included all patients who 
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were randomly assigned to the maintenance study 
and underwent at least one efficacy assessment. 
The safety population comprised all patients who 
received at least one dose of study medication 
and underwent at least one safety assessment. 
Treatment groups were compared with the use of 
Kaplan–Meier survival estimates for the time to 
treatment failure for each patient, with censoring 
of data for patients who withdrew before the end 
of the study.20 Between-group differences in sur-
vival curves were assessed with the use of a log-
rank test.21
The magnitude of the treatment effect was esti-
mated by means of the hazard ratio obtained from 
an unadjusted Cox model. Hazard ratios were also 
estimated in subgroups stratified according to in-
duction therapy, race, and geographic region. The 
overall incidence of events and the event rates per 
100 person-years for both treatments are presented 
within subgroups. Secondary efficacy variables 
were analyzed by calculating hazard ratios from 
unadjusted Cox models. Sensitivity analyses for 
the primary end point were conducted, with adjust-
ment for covariates. Testing at the significance 
level of 0.05 was applied to the primary efficacy 
analysis and to any key secondary efficacy analy-
ses (with no adjustments for multiple compari-
sons). Safety variables were analyzed descriptively, 
with a between-group comparison of proportions 
of patients with adverse events.
Statistical analyses were performed with the use 
of SAS software, version 9.2 (SAS Institute). For 
analyses of changes from baseline over time (at the 
time of the last visit), the last-observation-carried-
forward method was used.
R esult s
Patients
A total of 227 patients were enrolled between 
January 25, 2006, and March 19, 2007 (72 in Asia, 
60 in Latin America, 47 in North America, 40 in 
Europe, 5 in South Africa, and 3 in Australia). Of 
the patients in this intention-to-treat population, 
116 were randomly assigned to mycophenolate 
mofetil and 111 to azathioprine. A total of 127 pa-
tients (55.9%) completed the 36 months of treat-
ment: 73 (62.9%) in the mycophenolate mofetil 
group and 54 (48.6%) in the azathioprine group 
(Fig. 1). The main reasons for early withdrawal 
227 Patients underwent randomization
116 Were assigned to receive mycophenolate
mofetil
111 Were assigned to receive azathioprine
43 Were withdrawn
29 Had adverse events
5 Were withdrawn by
physician
3 Withdrew consent
3 Were lost to follow-up
2 Were withdrawn by
sponsor
1 Did not comply with
the study regimen
57 Were withdrawn
43 Had adverse events
4 Were withdrawn by
physician
3 Were withdrawn by
sponsor
3 Withdrew consent
1 Was lost to follow-up
1 Stopped study medi-
cation after 14 days
1 Did not comply with
the study regimen
1 Died
73 Completed the study 54 Completed the study
Figure 1. Treatment Assignments and Withdrawal in the Intention-to-Treat Population.
Some but not all of the patients who were withdrawn from the study reached the primary end point (treatment failure).
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in both groups were adverse events and flares of 
lupus nephritis. There were no significant differ-
ences between the groups with respect to demo-
graphic or disease characteristics (Table 1).
Immunosuppressive Therapies
The safety population comprised 226 patients, of 
whom 115 received mycophenolate mofetil and 
111 received azathioprine. Mean (±SD) doses of 
mycophenolate mofetil and azathioprine were 
1.87±0.43 g and 119.7±47.91 mg, respectively. The 
proportion of patients whose average daily dose 
was 80% or more of the target dose was 79.7% for 
mycophenolate mofetil and 82.6% for azathioprine. 
In a subgroup analysis of patients for whom treat-
ment failed, the mean doses were 1.89±0.52 g and 
123.3±49.73 mg, respectively. The mean treatment 
duration was 834.4±363 days for mycophenolate 
mofetil and 727.2±405 days for azathioprine. The 
majority of patients received 10 mg of prednisone 
per day or less throughout the study: 104 patients 
(90.4%) and 96 patients (86.5%) in the mycopheno-
late mofetil and azathioprine groups, respectively.
Study End Points
Mycophenolate mofetil was significantly superior 
to azathioprine with respect to the primary end 
point, time to treatment failure (hazard ratio for 
treatment failure, 0.44; 95% confidence interval 
[CI], 0.25 to 0.77; P = 0.003) (Fig. 2). Overall ob-
served rates of treatment failure were 16.4% (19 of 
116 patients) in the mycophenolate mofetil group 
and 32.4% (36 of 111) in the azathioprine group. 
The superiority of mycophenolate mofetil was con-
sistent, regardless of induction therapy, race, and 
geographic region (Fig. 3).
Mycophenolate mofetil was also superior to 
azathioprine with respect to individual compo-






Sex — no. of patients (%)
Male 17 (14.7) 15 (13.5)
Female 99 (85.3) 96 (86.5)
Race — no. of patients (%)†
White 48 (41.4) 51 (45.9)
Black 12 (10.3) 11 (9.9)
Asian 39 (33.6) 37 (33.3)
Other 17 (14.7) 12 (10.8)
Ethnic group — no. of patients (%)
Hispanic 36 (31.0) 41 (36.9)
Non-Hispanic 80 (69.0) 70 (63.1)
Age at time of informed consent — yr 31.8±10.59 31.0±10.77
Weight — kg 64.7±16.64 64.0±16.12
Duration of lupus nephritis — yr‡ 3.1±4.64 2.9±4.20
Duration of systemic lupus erythematosus — yr‡ 5.8±6.41 4.9±5.62
Renal-biopsy active class — no. of patients (%)§
III or III + V 17 (14.7) 12 (10.8)
IV or IV + V 81 (69.8) 82 (73.9)
V only 18 (15.5) 17 (15.3)
Urinary protein — mg/24 hr 906±819.93 820.0±754.33
Urinary protein:creatinine ratio¶ 0.97±1.413 0.75±0.830
Serum creatinine — mg/dl‖ 0.82±0.24 0.90±0.38
eGFR — ml/min/1.73 m2** 104.9±43.13 98.6±38.22
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nents of treatment failure, including the time to 
renal flare (hazard ratio for flare, 0.50; 95% CI, 
0.26 to 0.93; P = 0.03). Renal flare occurred in 15 
of 116 patients (12.9%) given mycophenolate 
mofetil versus 26 of 111 patients (23.4%) given 
azathioprine (Fig. 2). The time to rescue therapy 
for lupus nephritis was also longer with myco-
phenolate mofetil than with azathioprine (haz-
ard ratio, 0.39; 95% CI, 0.18 to 0.87; P = 0.02); the 
rates of rescue were 7.8% (9 of 116 patients) and 
17.1% (19 of 111), respectively.
Mycophenolate mofetil was significantly supe-
rior to azathioprine for the key secondary end 
points of the broader definition of treatment fail-
ure (rate, 42.2% [49 of 116 patients] in the myco-
phenolate mofetil group vs. 56.8% [63 of 111] in 
the azathioprine group; hazard ratio, 0.66; 95% CI, 
0.46 to 0.97; P = 0.03), and the time to documented 
or suspected renal flare (rate, 21.6% [25 of 116 
patients] vs. 36.0% [40 of 111], respectively; hazard 
ratio, 0.56; 95% CI, 0.35 to 0.89; P = 0.01). All other 
components of the primary efficacy end point 
showed a numerical benefit in favor of mycophe-
nolate mofetil, including the time to end-stage re-
nal disease (rate, 0% [0 of 116 patients] in the 
mycophenolate mofetil group vs. 2.7% [3 of 111] in 
the azathioprine group; P = 0.07), and the time to 
sustained doubling of the serum creatinine level 
(rate, 0.9% [1 of 116 patients] vs. 4.5% [5 of 111], 
respectively; P = 0.07). The benefit of mycopheno-
late mofetil was maintained after adjustments were 
made for the serum creatinine level (P = 0.004) and 
the estimated glomerular filtration rate at the end 
of induction therapy (P = 0.004). The rates of major 
extrarenal f lares were low: 6.9% (8 of 116 pa-
tients) in the mycophenolate mofetil group and 
6.3% (7 of 111) in the azathioprine group. The 
time to a major extrarenal flare did not differ 
significantly between the two groups (P = 0.94).







eGFR category — no. of patients (%)**
≥90 ml/min/1.73 m2 71 (61.2) 62 (55.9)
≥60 to <90 ml/min/1.73 m2 34 (29.3) 33 (29.7)
≥30 to <60 ml/min/1.73 m2 11 (9.5) 15 (13.5)
≥15 to <30 ml/min/1.73 m2 0 1 (0.9)
Active urinary sediment — no. of patients (%)†† 65 (56.0) 70 (63.1)
Immunologic factors‡‡
Serum C3 — mg/dl 95.1±25.13 93.3±28.67
Serum C4 — mg/dl 18.6±10.06 19.2±10.26
Anti–double-stranded DNA antibodies — IU/ml 62.2±56.73 57.7±48.72
*  Plus–minus values are means ±SD. There were no significant differences between the two treatment groups with re-
spect to any of the demographic or baseline clinical characteristics. Demographic characteristics (sex, race, ethnic 
group, and age at time of consent) and renal-biopsy class were determined only at the start of induction therapy. 
Durations refer to the time since the start of maintenance therapy. Reference ranges are as follows: urinary 
protein:creatinine ratio (mg:mg), 0.015 to 0.220; serum creatinine, 0.49 to 1.40 mg per deciliter; estimated glomerular 
filtration rate (eGFR), 90 to 120 ml per minute per 1.73 m2 of body-surface area; and anti–double-stranded DNA anti-
bodies, <30 IU per milliliter.
†  Race was self-reported.
‡  Duration refers to the length of time the disease had been present at the start of induction therapy.
§  The renal-biopsy specimens were classified according to the International Society of Nephrology and Renal Pathology 
Society 2003 Classification of Lupus Nephritis17 and are described in the protocol at NEJM.org.
¶  The unit of measurement was mg:mg.
‖  To convert the values for creatinine to micromoles per liter, multiply by 88.4.
** The estimated glomerular filtration rate is calculated with the use of the Modification of Diet in Renal Disease formula17,22: 
186 × (serum creatinine in mg/dl)−1.154 × age−0.203 × 1.21 if black × 0.742 if female.
†† An active urinary sediment is defined as the presence of more than 5 white cells per high-power field, more than 5 red cells 
per high-power field, a dipstick result of 2+ or more for blood, and red-cell casts in the absence of infection or other causes.
‡‡ Values are geometric means.
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titers of C3 and C4 in serum were lower in the 
azathioprine group than those in the mycopheno-
late mofetil group, and they remained lower 
throughout the study. Over time, there was a trend 
toward greater decreases in geometric mean titers 
of anti–double-stranded DNA antibodies in the 
patients treated with mycophenolate mofetil.
Safety and Tolerability
The incidence of adverse events during treatment 
was similar in the two groups: 98.3% (113 of 115 
patients given mycophenolate mofetil) and 97.3% 
(108 of 111 patients given azathioprine, P = 0.68) 
(Table 2). For additional details, see the Supple-
mentary Appendix.
Infections were the most common adverse 
events in both groups, with a rate of: 79.1% (91 of 
115 patients) in the mycophenolate mofetil group 
and 78.4% (87 of 111) in the azathioprine group. 
The rate of serious infections was low in both 
groups: 9.6% (11 of 115 patients) in the mycophe-
nolate mofetil group and 11.7% (13 of 111) in the 
azathioprine group.
The proportion of patients with adverse events 
leading to withdrawal was higher with azathio-
prine (39.6% [44 of 111 patients]) than with my-
cophenolate mofetil (25.2% [29 of 115], P = 0.02). 
Fewer patients in the mycophenolate mofetil group 
than in the azathioprine group had at least one 
serious adverse event, although the difference was 
not significant (23.5% [27 of 115 patients] vs. 
33.3% [37 of 111], P = 0.11). During the study, one 
death occurred in the azathioprine group and 
was due to a traffic accident. One case of cancer 
(uterine carcinoma in situ) was diagnosed in the 
azathioprine group.
Discussion
There are few data concerning maintenance ther-
apy for lupus nephritis.8,11 A suboptimal response 
to treatment in patients with class III, IV, or V lu-
pus nephritis increases the risk of end-stage renal 
disease.23 The early National Institutes of Health 
(NIH) regimen of intravenous cyclophosphamide 
became the standard of care in many countries 
but was challenged by a long-term maintenance 
trial showing that oral mycophenolate mofetil 
and oral azathioprine were each superior to the 
standard 2-year NIH cyclophosphamide regi-
men.11 In an open-label study of maintenance ther-
apy in 105 patients with lupus nephritis, Houssiau 
et al.8 reported no significant difference in relapse 
rates between patients who were randomly as-
signed to receive azathioprine and those assigned 
to receive mycophenolate mofetil. Renal flares were 
observed in 10 of 53 patients given mycophenolate 
mofetil (18.9%), as compared with 13 of 52 patients 
given azathioprine (25.0%).
In our study, mycophenolate mofetil was su-
perior to azathioprine in maintaining the renal 
response and in preventing relapse in patients 





































































































































Figure 2. Kaplan–Meier Curves for Time to Treatment Failure and Time 
to Renal Flare.
The intention-to-treat population comprised 227 patients, of whom 116 were 
given mycophenolate mofetil and 111 were given azathioprine. Panel A shows 
the time to treatment failure, and Panel B shows the time to renal flare.
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to induction therapy with either mycophenolate 
mofetil or cyclophosphamide. There were few ne-
phritic flares, an expected finding, since the ma-
jority of patients entered the induction study with 
ongoing proteinuria rather than clinical nephritis. 
Even when broader end-point criteria were applied, 
mycophenolate mofetil proved superior to azathio-
prine. The results for other key secondary end 
points also confirmed the superiority of mycophe-
nolate mofetil over azathioprine — findings that 
were consistent regardless of the induction thera-
py received, race, and geographic region.
Rates of complete remission at the end of in-
duction therapy were low (8.6% with mycopheno-
late mofetil and 8.1% with cyclophosphamide).13 
Although the aim of the study was to prevent re-
lapse, patients in both treatment groups continued 
to have improvement, with complete remission 
eventually achieved in 62.1% of patients in the 
mycophenolate mofetil group (72 of 116) and in 
59.5% of those in the azathioprine group (66 of 
111). This finding suggests that the distinction 
between induction therapy and maintenance ther-
apy in patients with lupus nephritis may be an 
artificial one.
Little extrarenal lupus activity was observed in 
either group at the start of maintenance therapy 
or at the end of the study, which probably reflects 
the requirement of a clinical response for entry 
into the maintenance study. Adverse events were 
common in both groups and were consistent with 
previous findings.8,11,13 One death occurred in 
the azathioprine group and the frequency of seri-
ous infections was low in both groups. Azathio-
prine was associated with adverse hematologic 
events (a finding that is consistent with its 
known safety profile), and serious adverse events 
and withdrawals from the study were also more 
common in this treatment group.
This study was not powered to draw conclu-
sions about subsets of patients. Few repeat renal 
biopsies were performed during the study, which 
also limits the ability to draw conclusions about 
possible treatment benefits with respect to active 
disease or chronic renal damage.
Although our trial included more patients and 
was substantially longer than many of the con-
trolled trials involving patients with lupus nephri-
tis,6-8,11,24 potential outcomes that might appear 
more frequently after 5 to 20 years (e.g., cardiovas-
cular complications and end-stage renal disease) 
cannot be determined, since no further follow-up 
study is planned. The length of time that treat-
ment with mycophenolate mofetil needs to be 
continued is unknown; hence, improved biomark-
ers of response are needed to distinguish disease 
remission from remission that occurs while the 
patient is receiving treatment.
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Figure 3. Risk of Treatment Failure in Subgroups of Patients.
The incidence rate is the number of events per 100 person-years. The hazard ratio was derived from a Cox model, 
with treatment as the only factor, according to subgroup. “Rest of world” includes Europe (40 patients), South Africa 
(5 patients), and Australia (3 patients). IV denotes intravenous, and MMF mycophenolate mofetil.
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Patients who had a clinical response after 6 
months of induction therapy were included in this 
maintenance study. Those patients whose disease 
was more difficult to treat, therefore, may have 
been excluded. Since many black patients did not 
meet the clinical response criteria, few were in-
cluded in the maintenance trial. Most patients 
reached their target dose and remained in the 
maintenance study for the full 36 months. The 
study was adequately powered to assess the pri-
mary composite outcome, which was achieved, 
with results consistent across the treatment groups.
We conclude that mycophenolate mofetil is 
superior to azathioprine in maintaining the renal 
response to treatment and in preventing relapse 
in patients with active lupus nephritis who have 
had a clinical response to induction therapy with 
either mycophenolate mofetil or intravenous cyclo-
phosphamide.
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Table 2. Incidence of Adverse Events that Emerged during Treatment, and Most Frequent Serious Adverse Events, 





(N = 111) P Value
no. of patients (%)
All adverse events‡ 113 (98.3) 108 (97.3) 0.68
All serious adverse events 27 (23.5) 37 (33.3) 0.11
All adverse events leading to withdrawal 29 (25.2) 44 (39.6) 0.02
Serious adverse events not related to lupus
Death 0 1 (0.9) 0.49
Malignant conditions 0 1 (0.9) 0.49
Pneumonia 2 (1.7) 1 (0.9) 1.00
Appendicitis 0 2 (1.8) 0.24
Leukopenia 0 4 (3.6) 0.06
Systemic lupus erythematosus 3 (2.6) 2 (1.8) 1.00
Lupus nephritis 1 (0.9) 5 (4.5) 0.11
* The terms used to describe the events are those preferred by the Medical Dictionary for Regulatory Activities, version 12.0. 
Only adverse events that occurred during treatment are listed; these include any nonserious adverse event that  occurred 
between the date of the first dose and the date of the last visit plus 14 days and any serious adverse event that occurred 
after the date of the first dose. Multiple occurrences of the same adverse event in one person were counted only once.
† One patient in this group was randomly assigned to treatment in error and did not receive the study drug.
‡ This category includes all patients who had at least one adverse event.
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